Zhitong Finance App News, Goli Pharmaceutical-B (01672.HK) announced that ASC30's global phase III clinical program for long-term weight management has completed the first patient administration. ASC30 is Goli's proprietary once-daily small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist under clinical study, developed for long-term weight management and diabetes treatment.

Zhitongcaijing · 1d ago
Zhitong Finance App News, Goli Pharmaceutical-B (01672.HK) announced that ASC30's global phase III clinical program for long-term weight management has completed the first patient administration. ASC30 is Goli's proprietary once-daily small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist under clinical study, developed for long-term weight management and diabetes treatment.